OrbiMed and New Enterprise Associates News

This is selected news for OrbiMed and New Enterprise Associates, which are filed under Sectors / Healthtech and Capital Firms, respectively. There are 16 news items for this page.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source
11/14/2022 MBX Biosciences Closes $115 Million Series B Financing to
... by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board. ‚AuMBX has grown tremendously as a company ...
Globe Newswire
11/14/2022 MBX Biosciences closes on $115M in drug-development funding – Indianapolis Business Journal
... Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners, along with existing investors Frazier Life Sciences, New Enterprise Associates and OrbiMed. ‚AuThis latest raise really will help us achieve our mission of pioneering precision endocrine peptides and help people with endocrine ...
ibj.com
11/14/2022 MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
... by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board. ‚AuMBX has grown tremendously as a company ...
forextv.com
11/14/2022 MBX Biosciences Closes $115 Million Series B Financing to Advance Development of Endocrine Disease Programs
... Series B financing was led by Wellington Management with participation from RA Capital Management and Norwest Venture Partners along with existing investors Frazier Life Sciences, New Enterprise Associates (NEA) and OrbiMed. In addition, Tiba Aynechi, Ph. D., general partner at Norwest Venture Partners, will join the MBX board. ‚AuMBX has ...
biotechwinners.com
2/11/2021 VistaGen Therapeutics Reports Fiscal 2021 Third Quarter Financial Results and Provides Update on Expected Clinical Studies in Calendar 2021
... the most recent quarter, closing a $100 million financing which involved significant participation from leading healthcare institutional investors such as Acuta Capital, New Enterprise Associates, OrbiMed and Venrock Healthcare Capital Partners, among others. We are encouraged by these transformative milestones. Together, they have further advanced our tenacious pursuit to bring ...
vistagen.com
12/24/2020 $VTGN Closes $100M Underwritten Public Offering
... convertible preferred stock at a public offering price of $21.16 per share. All of the securities in the offering were sold by VistaGen. Acuta Capital, New Enterprise Associates (‚AuNEA‚Au), OrbiMed and Venrock Healthcare Capital Partners, among others, participated in the offering as lead investors. VistaGen intends to use the ...
traderpower.com
12/23/2020 VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
... All of the securities in the offering were sold by VistaGen. Lead investors that participated in the offering include Acuta Capital, New Enterprise Associates (NEA), OrbiMed and Venrock Healthcare Capital Partners, among others. Each share of the Series D Preferred Stock is convertible into 23 shares of Common Stock at ...
FirstWord PHARMA
12/22/2020 VistaGen Therapeutics Announces Closing of $100 Million Underwritten Public Offering
... of $21.16 per share. All of the securities in the offering were sold by VistaGen. Lead investors that participated in the offering include Acuta Capital, New Enterprise Associates (NEA), OrbiMed and Venrock Healthcare Capital Partners, among others. Each share of the Series D Preferred Stock is convertible into 23 shares ...
vistagen.com
7/27/2020 MBX Biosciences debuts with $35M to advance treatments for rare endocrine diseases
... companies, MBX is based on work out of his lab at Indiana University. It starts out with $34.6 million in funding from Frazier Healthcare Partners, OrbiMed, New Enterprise Associates, Indiana Philantrhopic Venture Fund, Indiana Seed Fund III and Twilight Venture Partners. The capital will advance a pipeline of preclinical-stage ...
FierceBiotech
7/17/2020 Verona Pharma Raises $200 Million in Oversubscribed Private Placement and Subscription London VRP
... Access Biotechnology, Perceptive Advisors, Acorn Bioventures, PBM Capital, Samsara BioCapital, Foresite Capital, Sphera, Fairmount and Soleus Capital, as well as additional investors. Existing investors, OrbiMed, New Enterprise Associates (NEA), Vivo Capital, Abingworth, Novo Holdings A/S, Polar Capital and Aisling Capital also participated. Jefferies LLC (“Jefferies”) is acting as the ...
Globe Newswire
5/29/2020 For That Business Seeking Out Business Cash
... companies establishing novel therapeutics. Versant's website has that given that its inception in 1999, it provides helped over 65 organizations achieve successful acquisitions or IPOs. OrbiMed Healthcare Fund Management Amount of Deals due to the fact January 1st, 2013: 37 Website: www.orbimed.com Portfolio Highlights: MID Labs, Glaukos, Proteus Digital Health ...
awdalpress.com
3/30/2020 The 1Q20 IPO market’s most active venture capital firms - Nasdaq
... drove venture exits in the quarter, producing nine IPOs, but the absence of tech unicorns weighed on venture activity. The quarter's most active venture firm New Enterprise Associates was the lead investor on two IPOs, while healthcare VCs Third Rock Ventures , OrbiMed Advisors , Versant Ventures , and Frazier Healthcare Partners were ...
Nasdaq
3/7/2020 CTI BioPharma Announces Closing of Rights Offering
... Partners L.P. purchased 3,047 shares of Series X Preferred, Stonepine Capital, LP purchased 3,267,127 shares of Common Stock and 673.2873 shares of Series X Preferred, OrbiMed Private Investments VI, LP purchased 4,520,600 shares of Common Stock and 298 shares of Series X Preferred and New Enterprise Associates, Inc. purchased 3,390,450 ...
PR Newswire
2/18/2020 Crossover round, check. New team of biopharma execs, check. Now, Imara wants an IPO
... including bone marrow suppression and infertility. By proposing a way to improve on the risk-benefit profile of hydroxyurea, Imara attracted investment from backers including New Enterprise Associates (NEA) and Pfizer Venture Investments to support its advance into clinical trials. Three years later, in March 2019, Imara grew its investor ...
FierceBiotech
2/14/2020 CTI BioPharma Announces Commencement of Rights Offering
... 2020 through 5:00 p.m. , New York time, on March 2, 2020 . The Rights Offering will be fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP and New Enterprise Associates, Inc. (the "Backstop Investors") each of which have agreed to purchase its respective as-converted pro ...
PR Newswire
2/3/2020 CTI BioPharma Announces Proposed Rights Offering
... the $60 million offering amount. The rights offering will be fully backstopped by BVF Partners L.P., Stonepine Capital, L.P., OrbiMed Private Investments VI, LP and New Enterprise Associates, Inc. each of which have agreed to purchase, at a minimum, its respective as-converted pro rata share of the offering amount ...
PR Newswire
8/27/2019 VC-backed Pionyr names Levey as SVP and chief business officer
... senior vice president and chief business officer. Previously, Levey worked at Tempest Therapeutics where she was vice president and chief business officer. Pionyr's backers included OrbiMed, New Enterprise Associates, Sofinnova, SV Health Investors, Vida Ventures, Trinitas Capital, Mission Bay Capital and Osage University Partners. PRESS RELEASE SOUTH SAN FRANCISCO, Aug ...
PE Hub
12/13/2017 Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based Therapeutics Targeting the Tumor Microenvironment
... million Series B investment round. This brings total funding since the company's founding in 2015 to $72 million . The Series B financing was led by New Enterprise Associates and included Sofinnova Ventures and Vida Ventures, along with Pionyr's existing investors, OrbiMed, SV Health Investors, Osage University Partners, and Mission Bay ...
PR Newswire
12/13/2017 Pionyr Immunotherapeutics Completes $62 Million Series B Financing to Advance Antibody-based
... to $72 million . The Series B financing was led by New Enterprise Associates and included Sofinnova Ventures and Vida Ventures, along with Pionyr's existing investors, OrbiMed, SV Health Investors, Osage University Partners, and Mission Bay Ventures. Research conducted at Pionyr over the past year shows that its most advanced technology ...
PR Newswire
12/13/2017 Why this startup is playing in one of the hottest areas of cancer
... of drug development's hottest spaces with a fresh round of $62 million. Pionyr Immunotherapeutics Inc. said Wednesday that its Series B round was led by New Enterprise Associates and included Sofinnova Ventures and Vida Ventures and involved existing investors OrbiMed, SV Health Investors, Osage University Partners and Mission Bay Ventures ...
The Business Journals